| 1. |
- Yewale, Priti, et al.
(författare)
-
Studies on Biosmotrap : A multipurpose biological air purifier to minimize indoor and outdoor air pollution
- 2022
-
Ingår i: Journal of Cleaner Production. - : Elsevier. - 0959-6526 .- 1879-1786. ; 357
-
Tidskriftsartikel (refereegranskat)abstract
- Air pollution is a serious health concern that affects many people across the globe. The major air pollutants are particulate matter, carbon oxides, nitrogen oxides, sulphur oxides, volatile organic compounds, polycyclic aromatics and free radicals which cause severe respiratory distress and infections. The existing air cleaning systems suffer from drawbacks of high cost and generation of secondary pollutants. A novel biological air filter “Biosmotrap” which is a laminate composite of sponge gourd and algae was developed. Biosmotrap placed in a carrier assembly on exhaust of vehicles, could remove carbon monoxide, nitric oxide, nitrogen dioxide, and fine particulate matter (PM2.5) from the vehicular emissions resulting in cleaner emissions. Biosmotrap decreased carbon monoxide from 1,423,992 μg/m3 to 76,756 μg/m3, nitric oxide from 71,128 μg/m3 to 9982 μg/m3, nitrogen dioxide from 565 μg/m3 to 188 μg/m3 and PM2.5 from 3200 μg/m3 to 60 μg/m3 from a polluting vehicle. Biosmotrap removed 60–80% of indoor pollutants from cigarette smoke and incense-stick smoke. Biosmotrap could protect the human cells from oxidative DNA damage induced by indoor air pollutants. Hibiscus rosa-sinensis plants exposed to air filtered through Biosmotrap were healthy as compared to the plants directly exposed to polluted air. Biosmotrap is an economic, efficient, eco-friendly filter that is superior to existing air filtration methods.
|
|
| 2. |
- Visuttijai, Kittichate, 1979-, et al.
(författare)
-
Lowered Expression of Tumor Suppressor Candidate MYO1C Stimulates Cell Proliferation, Suppresses Cell Adhesion and Activates AKT
- 2016
-
Ingår i: PLOS ONE. - : Public Library of Science. - 1932-6203. ; 11:10
-
Tidskriftsartikel (refereegranskat)abstract
- Myosin-1C (MYO1C) is a tumor suppressor candidate located in a region of recurrent losses distal to TP53. Myo1c can tightly and specifically bind to PIP2, the substrate of Phosphoinositide 3-kinase (PI3K), and to Rictor, suggesting a role for MYO1C in the PI3K pathway. This study was designed to examine MYO1C expression status in a panel of well-stratified endometrial carcinomas as well as to assess the biological significance of MYO1C as a tumor suppressor in vitro. We found a significant correlation between the tumor stage and lowered expression of MYO1C in endometrial carcinoma samples. In cell transfection experiments, we found a negative correlation between MYO1C expression and cell proliferation, and MYO1C silencing resulted in diminished cell migration and adhesion. Cells expressing excess of MYO1C had low basal level of phosphorylated protein kinase B (PKB, a.k.a. AKT) and cells with knocked down MYO1C expression showed a quicker phosphorylated AKT (pAKT) response in reaction to serum stimulation. Taken together the present study gives further evidence for tumor suppressor activity of MYO1C and suggests MYO1C mediates its tumor suppressor function through inhibition of PI3K pathway and its involvement in loss of contact inhibition.
|
|
| 3. |
- Frykholm, Karolin, 1977, et al.
(författare)
-
Fast size-determination of intact bacterial plasmids using nanofluidic channels
- 2015
-
Ingår i: Lab on a Chip. - : Royal Society of Chemistry (RSC). - 1473-0189 .- 1473-0197. ; 15:13, s. 2739-2743
-
Tidskriftsartikel (refereegranskat)abstract
- We demonstrate how nanofluidic channels can be used as a tool to rapidly determine the number and sizes of plasmids in bacterial isolates. Each step can be automated at low cost, opening up opportunities for general use in microbiology labs.
|
|
| 4. |
- Nawaz, Muhammad, et al.
(författare)
-
Lipid Nanoparticles Deliver the Therapeutic VEGFA mRNA In Vitro and In Vivo and Transform Extracellular Vesicles for Their Functional Extensions
- 2023
-
Ingår i: Advanced Science. - : John Wiley & Sons. - 2198-3844. ; 10:12
-
Tidskriftsartikel (refereegranskat)abstract
- Lipid nanoparticles (LNPs) are currently used to transport functional mRNAs, such as COVID-19 mRNA vaccines. The delivery of angiogenic molecules, such as therapeutic VEGF-A mRNA, to ischemic tissues for producing new blood vessels is an emerging strategy for the treatment of cardiovascular diseases. Here, the authors deliver VEGF-A mRNA via LNPs and study stoichiometric quantification of their uptake kinetics and how the transport of exogenous LNP-mRNAs between cells is functionally extended by cells’ own vehicles called extracellular vesicles (EVs). The results show that cellular uptake of LNPs and their mRNA molecules occurs quickly, and that the translation of exogenously delivered mRNA begins immediately. Following the VEGF-A mRNA delivery to cells via LNPs, a fraction of internalized VEGF-A mRNA is secreted via EVs. The overexpressed VEGF-A mRNA is detected in EVs secreted from three different cell types. Additionally, RNA-Seq analysis reveals that as cells’ response to LNP-VEGF-A mRNA treatment, several overexpressed proangiogenic transcripts are packaged into EVs. EVs are further deployed to deliver VEGF-A mRNA in vitro and in vivo. Upon equal amount of VEGF-A mRNA delivery via three EV types or LNPs in vitro, EVs from cardiac progenitor cells are the most efficient in promoting angiogenesis per amount of VEGF-A protein produced. Intravenous administration of luciferase mRNA shows that EVs could distribute translatable mRNA to different organs with the highest amounts of luciferase detected in the liver. Direct injections of VEGF-A mRNA (via EVs or LNPs) into mice heart result in locally produced VEGF-A protein without spillover to liver and circulation. In addition, EVs from cardiac progenitor cells cause minimal production of inflammatory cytokines in cardiac tissue compared with all other treatment types. Collectively, the data demonstrate that LNPs transform EVs as functional extensions to distribute therapeutic mRNA between cells, where EVs deliver this mRNA differently than LNPs.
|
|
| 5. |
- Javeed, Ashir, 1989-, et al.
(författare)
-
Breaking barriers : a statistical and machine learning-based hybrid system for predicting dementia
- 2023
-
Ingår i: Frontiers in Bioengineering and Biotechnology. - : Frontiers Media S.A.. - 2296-4185. ; 11
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: Dementia is a condition (a collection of related signs and symptoms) that causes a continuing deterioration in cognitive function, and millions of people are impacted by dementia every year as the world population continues to rise. Conventional approaches for determining dementia rely primarily on clinical examinations, analyzing medical records, and administering cognitive and neuropsychological testing. However, these methods are time-consuming and costly in terms of treatment. Therefore, this study aims to present a noninvasive method for the early prediction of dementia so that preventive steps should be taken to avoid dementia. Methods: We developed a hybrid diagnostic system based on statistical and machine learning (ML) methods that used patient electronic health records to predict dementia. The dataset used for this study was obtained from the Swedish National Study on Aging and Care (SNAC), with a sample size of 43040 and 75 features. The newly constructed diagnostic extracts a subset of useful features from the dataset through a statistical method (F-score). For the classification, we developed an ensemble voting classifier based on five different ML models: decision tree (DT), naive Bayes (NB), logistic regression (LR), support vector machines (SVM), and random forest (RF). To address the problem of ML model overfitting, we used a cross-validation approach to evaluate the performance of the proposed diagnostic system. Various assessment measures, such as accuracy, sensitivity, specificity, receiver operating characteristic (ROC) curve, and Matthew’s correlation coefficient (MCC), were used to thoroughly validate the devised diagnostic system’s efficiency. Results: According to the experimental results, the proposed diagnostic method achieved the best accuracy of 98.25%, as well as sensitivity of 97.44%, specificity of 95.744%, and MCC of 0.7535. Discussion: The effectiveness of the proposed diagnostic approach is compared to various cutting-edge feature selection techniques and baseline ML models. From experimental results, it is evident that the proposed diagnostic system outperformed the prior feature selection strategies and baseline ML models regarding accuracy.
|
|
| 6. |
- Johansson, Markus, et al.
(författare)
-
Data Mining Identifies CCN2 and THBS1 as Biomarker Candidates for Cardiac Hypertrophy
- 2022
-
Ingår i: Life-Basel. - : MDPI AG. ; 12:5
-
Tidskriftsartikel (refereegranskat)abstract
- Cardiac hypertrophy is a condition that may contribute to the development of heart failure. In this study, we compare the gene-expression patterns of our in vitro stem-cell-based cardiac hypertrophy model with the gene expression of biopsies collected from hypertrophic human hearts. Twenty-five differentially expressed genes (DEGs) from both groups were identified and the expression of selected corresponding secreted proteins were validated using ELISA and Western blot. Several biomarkers, including CCN2, THBS1, NPPA, and NPPB, were identified, which showed significant overexpressions in the hypertrophic samples in both the cardiac biopsies and in the endothelin-1-treated cells, both at gene and protein levels. The protein-interaction network analysis revealed CCN2 as a central node among the 25 overlapping DEGs, suggesting that this gene might play an important role in the development of cardiac hypertrophy. GO-enrichment analysis of the 25 DEGs revealed many biological processes associated with cardiac function and the development of cardiac hypertrophy. In conclusion, we identified important similarities between ET-1-stimulated human-stem-cell-derived cardiomyocytes and human hypertrophic cardiac tissue. Novel putative cardiac hypertrophy biomarkers were identified and validated on the protein level, lending support for further investigations to assess their potential for future clinical applications.
|
|
| 7. |
- Pokrzywa, Malgorzata, 1977, et al.
(författare)
-
Developmental MYH3 Myopathy Associated with Expression of Mutant Protein and Reduced Expression Levels of Embryonic MyHC
- 2015
-
Ingår i: PLoS One. - : Public Library of Science (PLoS). - 1932-6203. ; 10:11
-
Tidskriftsartikel (refereegranskat)abstract
- Objective An essential role for embryonic MyHC in foetal development has been found from its association with distal arthrogryposis syndromes, a heterogeneous group of disorders characterised by congenital contractions. The latter probably result from severe myopathy during foetal development. Lack of embryonic muscle biopsy material and suitable animal models has hindered study of the pathomechanisms linking mutations in MYH3 to prenatal myopathy. We determined the pathomechanisms of developmental myopathy caused by recurrent p. Thr178Ile MYH3 heterozygosity, using patient-derived skeletal muscle cells in culture as an experimental disease model to emulate early embryonic development. These cultured cells were processed for discrimination and quantitative analysis of mutant and wild-type MYH3 alleles and MyHC transcripts, real-time RT-qPCR, sequence analysis, immunofluorescence microscopy, immunoblot, and proteomic assessments. Involvement of the ubiquitin proteasome system was investigated in patients with p. Thr178Ile mutations in MYH3 and MYH2. We found equal overall expression of mutant and wild-type MyHC mRNAs and proteins. Compared to the controls, however, expression of embryonic MyHC transcripts and proteins was reduced whereas expression of myosin-specific E3 ubiquitin ligase (MuRF1) was increased. We also found delayed myofibrillogenesis and atrophic myotubes but structured sarcomeres. In conclusion, this study suggests that developmental p.Thr178Ile MYH3 myopathy is associated with a combined pathomechanism of insufficient dosage of functional embryonic MyHC and production of mutant protein.
|
|
| 8. |
- Beheshtinia, Mohammad Ali, et al.
(författare)
-
Prioritizing healthcare waste disposal methods considering environmental health using an enhanced multi-criteria decision-making method
- 2023
-
Ingår i: Environmental Pollutants and Bioavailability. - : Taylor & Francis Group. - 2639-5932 .- 2639-5940. ; 35:1, s. 250-269
-
Tidskriftsartikel (refereegranskat)abstract
- The Healthcare Waste Disposal Method Selection (HCWDMS) is a complicated problem due to multiple and often contradictory criteria with different importance degrees. Thus, decision-makers are restored to multi-criteria decision-making (MCDM) methods to prioritize and select the best HCW disposal methods. This study introduces an enhanced MCDM method to deal with the HCWDMS problem. To address the problem, a comprehensive list of criteria and HCW disposal methods are identified. All the criteria are categorized into four main criteria, and Fuzzy Analysis Hierarchy Process is used to determine the weights of considered criteria and sub-criteria. The study results show that environmental, economic, technical, and social criteria are the most important in selecting disposal methods, respectively. Moreover, the sub-criteria of ‘Health Risk’, ‘Release with health effects’, and ‘Capital cost’ have the highest importance, respectively. Additionally, the methods of ‘Microwave’, ‘Sterilization by autoclave’, and ‘Reverse polymerization’ have the highest priority, respectively.
|
|
| 9. |
- Enroth, Helena, et al.
(författare)
-
Evaluation of QuickFISH and maldi Sepsityper for identification of bacteria in bloodstream infection
- 2019
-
Ingår i: Infectious Diseases. - : Taylor & Francis. - 2374-4235 .- 2374-4243. ; 51:4, s. 249-258
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Early detection of bacteria and their antibiotic susceptibility patterns are critical to guide therapeutic decision-making for optimal care of septic patients. The current gold standard, blood culturing followed by subculture on agar plates for subsequent identification, is too slow leading to excessive use of broad-spectrum antibiotic with harmful consequences for the patient and, in the long run, the public health. The aim of the present study was to assess the performance of two commercial assays, QuickFISH® (OpGen) and Maldi Sepsityper™ (Bruker Daltonics) for early and accurate identification of microorganisms directly from positive blood cultures.Materials and methods: During two substudies of positive blood cultures, the two commercial assays were assessed against the routine method used at the clinical microbiology laboratory, Unilabs AB, at Skaraborg Hospital, Sweden.Results: The Maldi Sepsityper™ assay enabled earlier microorganism identification. Using the cut-off for definite species identification according to the reference method (>2.0), sufficiently accurate species identification was achieved, but only among Gram-negative bacteria. The QuickFISH®assay was time-saving and showed high concordance with the reference method, 94.8% (95% CI 88.4–98.3), when the causative agent was covered by the QuickFISH® assay.Conclusions: The use of the commercial assays may shorten the time to identification of causative agents in bloodstream infections and can be a good complement to the current clinical routine diagnostics. Nevertheless, the performance of the commercial assays is considerably affected by the characteristics of the causative agents.
|
|
| 10. |
- Dahl-Halvarsson, Martin, et al.
(författare)
-
Myosin Storage Myopathy in C. elegans and Human Cultured Muscle Cells
- 2017
-
Ingår i: Plos One. - : Public Library of Science (PLoS). - 1932-6203. ; 12:1
-
Tidskriftsartikel (refereegranskat)abstract
- Myosin storage myopathy is a protein aggregate myopathy associated with the characteristic subsarcolemmal accumulation of myosin heavy chain in muscle fibers. Despite similar histological findings, the clinical severity and age of onset are highly variable, ranging from no weakness to severe impairment of ambulation, and usually childhood-onset to onset later in life. Mutations located in the distal end of the tail of slow/beta-cardiac myosin heavy chain are associated with myosin storage myopathy. Four missense mutations (L1793P, R1845W, E1883K and H1901L), two of which have been reported in several unrelated families, are located within or closed to the assembly competence domain. This location is critical for the proper assembly of sarcomeric myosin rod filaments. To assess the mechanisms leading to protein aggregation in myosin storage myopathy and to evaluate the impact of these mutations on myosin assembly and muscle function, we expressed mutated myosin proteins in cultured human muscle cells and in the nematode Caenorhabditis elegans. While L1793P mutant myosin protein efficiently incorporated into the sarcomeric thick filaments, R1845W and H1901L mutants were prone to formation of myosin aggregates without assembly into striated sarcomeric thick filaments in cultured muscle cells. In C. elegans, mutant alleles of the myosin heavy chain gene unc-54 corresponding to R1845W, E1883K and H1901L, were as effective as the wild-type myosin gene in rescuing the null mutant worms, indicating that they retain functionality. Taken together, our results suggest that the basis for the pathogenic effect of the R1845W and H1901L mutations are primarily structural rather than functional. Further analyses are needed to identify the primary trigger for the histological changes seen in muscle biopsies of patients with L1793P and E1883K mutations.
|
|
